TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway

Xu,Jinkai; Li,Zongyu; Su,Qinghua; Zhao,Jun; Ma,Jiancang

doi:10.3892/or.2017.5364

TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway

Authors:
- Jinkai Xu
- Zongyu Li
- Qinghua Su
- Jun Zhao
- Jiancang Ma
View Affiliations

Affiliations: Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: January 13, 2017 https://doi.org/10.3892/or.2017.5364
Pages: 1555-1564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer (TC) is a common malignancy of the endocrine system. Abnormal expression of tripartite motif-containing 29 (TRIM29) has been reported to promote tumorigenesis and predict poor prognosis in several human malignancies. The aim of this study was to assess the involvement of TRIM29 in the significance and prognosis of TC. Fifty-six tumor samples and their clinicopathological para-meters were obtained from TC patients; the expression level of TRIM29 was detected by RT-qPCR and western blotting. TRIM29 expression was knocked down by small interfering RNA (siRNA) among TT, TPC-1, and K1 cells to investigate the biological role of TRIM29 in TC cells. The results showed that TRIM29 expression was significantly increased in TC tissue samples and cells compared to normal tissues and cells (P<0.01, respectively). Overexpression of TRIM29 was associated with TNM stage (P<0.01), extrathyroidal extension (P<0.01), lymph node metastasis (P<0.05), and distant metastasis (P<0.05). Furthermore, the overall survival and disease-free rates of patients with high TRIM29 expression were decreased significantly compared with those with low TRIM29 expression (P<0.01, respectively). Knockdown of TRIM29 obviously suppressed cell proliferation; enhanced chemosensitivity to cisplatin; inhibited cell invasion and migration; caused cell cycle arrest at G0/G1 phase by decreasing cyclin B1, cyclin D1 and CDK2, while increasing p21 and p27; and induced cell apoptosis by enhancing the activities of caspase-3, caspase-9, and Bax, while decreased Bcl-2. Notably, decreased TRIM29 expression significantly inhibited the activation of P13K/AKT signaling pathway as well. Taken together, our findings suggested that TRIM29 played a crucial role in the progression and malignancy of TC, and silencing of TRIM29 exerted its antitumor effect by blocking P13K/AKT signaling pathway. Thus, TRIM29 might be a potential therapeutic target for the treatment of TC.

View Figures

View References

1	Zhang X, Wang Z, Tian L, Xie J, Zou G and Jiang F: Increased expression of FGF19 contributes to tumor progression and cell motility of human thyroid cancer. Otolaryngol Head Neck Surg. 154:52–58. 2016. View Article : Google Scholar : PubMed/NCBI
2	Kong LL, Man DM, Wang T, Zhang GA and Cui W: siRNA targeting RBP2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cells. Oncol Lett. 10:3393–3398. 2015.PubMed/NCBI
3	Ye WC, Gao L, Huang J, Fang XM and Xie G: Suppressed Krüppel-like factor 17 expression induces tumor proliferation, metastasis and a poor prognosis in papillary thyroid carcinoma. Mol Med Rep. 10:2087–2092. 2014.PubMed/NCBI
4	Hatakeyama S: TRIM proteins and cancer. Nat Rev Cancer. 11:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
5	Napolitano LM and Meroni G: TRIM family: Pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life. 64:64–71. 2012. View Article : Google Scholar : PubMed/NCBI
6	Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F and Pelicci PG: TRIM proteins in cancer. Adv Exp Med Biol. 770:77–91. 2012. View Article : Google Scholar : PubMed/NCBI
7	Song X, Fu C, Yang X, Sun D, Zhang X and Zhang J: Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer. Oncol Lett. 10:2283–2288. 2015.PubMed/NCBI
8	Sun H, Dai X and Han B: TRIM29 as a novel biomarker in pancreatic adenocarcinoma. Dis Markers. 2014:3178172014. View Article : Google Scholar : PubMed/NCBI
9	Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007. View Article : Google Scholar : PubMed/NCBI
10	Liu C, Huang X, Hou S, Hu B and Li H: Silencing of tripartite motif (TRIM) 29 inhibits proliferation and invasion and increases chemosensitivity to cisplatin in human lung squamous cancer NCI-H520 cells. Thorac Cancer. 6:31–37. 2015. View Article : Google Scholar : PubMed/NCBI
11	Jiang T, Tang HM, Lu S, Yan DW, Yang YX and Peng ZH: Up-regulation of tripartite motif-containing 29 promotes cancer cell proliferation and predicts poor survival in colorectal cancer. Med Oncol. 30:7152013. View Article : Google Scholar : PubMed/NCBI
12	Ai L, Kim WJ, Alpay M, Tang M, Pardo CE, Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, et al: TRIM29 suppresses TWIST1 and invasive breast cancer behavior. Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
13	Kanno Y, Watanabe M, Kimura T, Nonomura K, Tanaka S and Hatakeyama S: TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta Histochem. 116:708–712. 2014. View Article : Google Scholar : PubMed/NCBI
14	Jin S, Borkhuu O, Bao W and Yang YT: Signaling pathways in thyroid cancer and their therapeutic implications. J Clin Med Res. 8:284–296. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yang X, Liu G, Xiao H, Yu F, Xiang X, Lu Y, Li W, Liu X, Li S and Shi Y: TPX2 overexpression in medullary thyroid carcinoma mediates TT cell proliferation. Pathol Oncol Res. 20:641–648. 2014. View Article : Google Scholar : PubMed/NCBI
16	Liu Z, Yang L, Teng X, Zhang H and Guan H: The involvement of CXCR7 in modulating the progression of papillary thyroid carcinoma. J Surg Res. 191:379–388. 2014. View Article : Google Scholar : PubMed/NCBI
17	Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et al: The tripartite motif family identifies cell compartments. EMBO J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI
18	Kapp LN, Painter RB, Yu LC, van Loon N, CW III Richard, James MR, Cox DR and Murnane JP: Cloning of a candidate gene for ataxia-telangiectasia group D. Am J Hum Genet. 51:45–54. 1992.PubMed/NCBI
19	Tan ST, Liu SY and Wu B: TRIM29 Overexpression promotes proliferation and survival of bladder cancer cells through NF-κB signaling. Cancer Res Treat. 48:1302–1312. 2016. View Article : Google Scholar : PubMed/NCBI
20	Masuda Y, Takahashi H, Sato S, Tomomori-Sato C, Saraf A, Washburn MP, Florens L, Conaway RC, Conaway JW and Hatakeyama S: TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. Nat Commun. 6:72992015. View Article : Google Scholar : PubMed/NCBI
21	Wang L, Yang H, Palmbos PL, Ney G, Detzler TA, Coleman D, Leflein J, Davis M, Zhang M, Tang W, et al: ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells. Cancer Res. 74:1778–1788. 2014. View Article : Google Scholar : PubMed/NCBI
22	Xu R, Hu J, Zhang T, Jiang C and Wang HY: TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer. Oncotarget. 7:28579–28591. 2016.PubMed/NCBI
23	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
24	Yuan Z, Villagra A, Peng L, Coppola D, Glozak M, Sotomayor EM, Chen J, Lane WS and Seto E: The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol. 30:3004–3015. 2010. View Article : Google Scholar : PubMed/NCBI
25	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
26	Malumbres M: Cyclins and related kinases in cancer cells. J BUON. 12 Suppl 1:S45–S52. 2007.PubMed/NCBI
27	Deryugina EI and Quigley JP: Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 44–46, 94–112. 2015.
28	Yoon SO, Park SJ, Yun CH and Chung AS: Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 36:128–137. 2003.PubMed/NCBI
29	Abarikwu SO and Farombi EO: Atrazine induces apoptosis of SH-SY5Y human neuroblastoma cells via the regulation of Bax/Bcl-2 ratio and caspase-3-dependent pathway. Pestic Biochem Physiol. 118:90–98. 2015. View Article : Google Scholar : PubMed/NCBI
30	Hsieh AC, Truitt ML and Ruggero D: Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer. 105:329–336. 2011. View Article : Google Scholar : PubMed/NCBI
31	Ávalos Y, Canales J, Bravo-Sagua R, Criollo A, Lavandero S and Quest AF: Tumor suppression and promotion by autophagy. BioMed Res Int. 2014:6039802014. View Article : Google Scholar : PubMed/NCBI
32	Xing M: Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 20:697–706. 2010. View Article : Google Scholar : PubMed/NCBI
33	Zhou XM, Sun R, Luo DH, Sun J, Zhang MY, Wang MH, Yang Y, Wang HY and Mai SJ: Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget. 7:13634–13650. 2016.PubMed/NCBI
34	Brzezianska E and Pastuszak-Lewandoska D: A minireview: The role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci (Landmark Ed). 16:422–439. 2011. View Article : Google Scholar : PubMed/NCBI